One meta-analysis assessing the relative risk of pancreatitis associated with vascular endothelial growth factor receptor (VEGFR) TKIs, such as cabozantinib, found a relative risk of TKI pancreatitis to be 1.95 compared to 1.89 in those not on TKI therapy. Pancreatitis, however, was not expressly mentioned as an adverse event in the randomized controlled trials for cabozantinib [6]. The gene discussed is KDR; the disease is pancreatitis.